Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Vaccine. 2010 Jul 12;28(31):4997–5004. doi: 10.1016/j.vaccine.2010.05.023

Fig. 5. Long term persistence of rAd-A27L mediated protective efficacy and immunogenicity.

Fig. 5

6 – 8 week old Balb/c mice were immunized i.m. with 1×109 pfu of rAd-A27L or rAd-empty control vaccine and challenged i.n. with 5LD50 VV-WR at 35 weeks post vaccination. Mice that sustained more than 30% loss of body mass as shown by data points below the dotted line (B) were euthanized. Survival (A) and weight loss (B) are shown as mean values for each group ± SEM. Sera were harvested one day prior to challenge and tested for neutralizing antibody responses by PRNT50 assay. The endpoint titer for the PRNT50 assay was defined as the greatest serum dilution that caused a 50% reduction in the number of plaques compared to the virus control wells.